Top Biopharmas Such As Abbott (ABT) And GlaxoSmithKline (GSK) Still Betting On "Messed Up" Indian Drugs Market
3/12/2014 7:12:43 AM
Global drugmakers have had a nauseous time in India's $14 billion market. Prices have dropped and valuable patents have been overruled as the authorities strive to make medicines affordable for the 70 percent of people living on less than $2 a day. From a regulatory perspective, the government has "messed up", as one top industry consultant put it.
Help employers find you! Check out all the jobs and post your resume.
comments powered by